Spinal Curvature, Mobility, and Low Back Pain Relationship in Women With and Without Urinary Incontinence

Ataturk Training and Research Hospital73 enrolled

Overview

The aim of this study was to investigate the relationship among sagittal spinal curvatures, mobility, and low back pain in women with and without urinary incontinence.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

SINGLE

Enrollment

Conditions

Urinary Incontinence

Interventions

Spinal Mouse® measurementDEVICE

The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.

Low back pain intensity measurementBEHAVIORAL

Low back pain intensity of the patients was questioned by Visual Analogue Scale

Urogenital symptoms measurementBEHAVIORAL

The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * aged between 20 and 65 years, * diagnosed with stress and mixed urinary incontinence * healthy women Exclusion Criteria: * Women with prior history of injury or surgery related to spine, * spinal deformity, * systemic pathology, * any rheumatologic disease, * neurologic condition, * symptomatic pelvic organ prolapse, * malignancy, * pregnancy

Outcomes

Primary Outcomes

Spinal curve and mobility, as measured by Spinal Mouse® device

Time frame: spinal curve and mobility will be followed through study completion, an average of 3 months

Secondary Outcomes

Low back pain, as measured by Visual Analog Scale

Time frame: Low back pain will be followed through study completion, an average of 3 months

Disability caused by low back pain, as measured by Oswestry Disability Index

Time frame: Disability will be followed through study completion, an average of 3 months

Urogenital symptoms, as measured by Urogenital Distress Inventory-6

Time frame: Urogenital symptoms will be followed through study completion, an average of 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.